Atopic Dermatitis Drugs Market

Atopic Dermatitis Drugs Market (Drug Type: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Atopic Dermatitis Drugs Market Outlook 2031

  • The global atopic dermatitis drugs market was valued at US$ 6.0 Bn in 2021
  • The global market is projected to advance at a CAGR of 14.7% from 2022 to 2031
  • The global atopic dermatitis drugs market is anticipated to reach more than US$ 29.4 Bn by the end of 2031

Analysts’ Viewpoint on Atopic Dermatitis Drugs Market Scenario

The global atopic dermatitis drugs market is expected to grow at a rapid pace during the forecast period due to the rise in prevalence and incidence of the disease across the globe. Surge in atopic dermatitis cases has increased the need for effective treatment drugs such as cyclosporine and atopic eczema antihistamine. Governments in various developed and developing countries are participating in programs to spread awareness about atopic dermatitis medications. Similarly, development of new drugs for treating atopic dermatitis and increase in clinical trials are boosting the demand for new improved treatments for atopic dermatitis. Thus, the global atopic dermatitis market forecast appears promising due to the increase in investment by companies in the development of new treatment drugs. For instance, Sanofi and Pfizer have introduced various drugs for the treatment of atopic dermatitis. These drugs have received the U.S. FDA approval.

Atopic Dermatitis Drugs Market

Atopic Dermatitis Drugs Market Introduction

Atopic dermatitis, also known as eczema, is a condition that affects the skin and causes itchiness, dryness, and inflammation. The condition can be chronic and tends to flare and spread sometimes. Atopic dermatitis drugs, including atopic eczema steroids, are used to treat eczema and reduce itchiness and other conditions caused by atopic dermatitis. The global atopic dermatitis drugs market size is projected to grow at a rapid pace during the forecast period owing to the rise in investment in research & development activities and novel pipeline drugs.

Request a sample to get extensive insights into the Atopic Dermatitis Drugs Market

Increase in Incidence of Atopic Dermatitis Driving Global Market

Dermatological disorders differ across the globe based on geographic location, climatic conditions, socioeconomic status, lifestyle, age, gender, heredity, and personal habits. According to the World Health Organization (WHO), more than 900 million people were affected with skin diseases in 2017, and the five common conditions, including atopic dermatitis, accounted for around 80% of the skin disorders. High prevalence and substantial rise in incidence rate of atopic dermatitis across the globe is the key factor driving the atopic dermatitis drugs market. Atopic dermatitis affects 15% to 20% children and 1% to 3% adults across the world per year. New approvals and commercialization of novel therapeutic drugs under clinical trial studies are projected to propel the global atopic dermatitis market size during the forecast period.

Rise in Demand for Biologics Propelling Global Market

Usage of biologic drugs in dermatology has changed the treatment procedure of dermatological disorders, especially atopic dermatitis. Leading biopharmaceutical companies are investing significantly in biologic product development, merger & acquisitions, and strategic collaborations. Atopic dermatitis has shown positive response to biologics, which has improved the overall quality of life. Hence, overall demand for biologic drugs for atopic dermatitis has increased. This trend is likely to continue in the next few years. Just one biologic product has been approved for the treatment of atopic dermatitis to date. Many more are in phase II clinical trials and are likely to receive approvals in the near future.

Request a custom report on Atopic Dermatitis Drugs Market

Inhibition of Causative Inflammatory Response to Fuel Biologics Segment

In terms of drug type, the biologics segment dominated the global atopic dermatitis drugs market, with around 76% share in 2021. The trend is projected to continue during the forecast period. The segment is anticipated to be driven by the rise in prevalence of atopic dermatitis, as biologics inhibit the inflammatory response that is responsible for the development of the disease. According to the Dermatology Therapeutics Area Working Group, global prevalence rate of atopic dermatitis stands at 8% to 15% in children.

Retail Pharmacies Segment Lead Global Market

In terms of distribution channel, the global atopic dermatitis drugs market has been segmented into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacies segment held major share of around 65% in 2021. Growth of the segment can be ascribed to the increase in purchasing power of patients and surge in the number of retail pharmacies.

Regional Outlook of Global Atopic Dermatitis Drugs Market

North America accounted for the largest share of around 46% of the global atopic dermatitis drugs market in 2021. This can be ascribed to large patient pool in the region that requires efficient and new therapies.

Europe held around 30% share of the global market in 2021. The market in the region is expected to grow at a faster pace from 2022 to 2031 due to the increase in focus on the development of health care infrastructure by governments and rise in demand for affordable, effective therapeutics among the significant patient population.

Asia Pacific accounted for larger market share than Latin America and Middle East & Africa in 2021. However, the market in Latin America is expected to grow at a faster pace than that in Middle East & Africa.

Analysis of Key Players in Global Atopic Dermatitis Drugs Market

The atopic dermatitis drugs market report concludes with the company profiles section, which includes key information about major players in the global atopic dermatitis drugs market. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global atopic dermatitis drugs market. Prominent players in the atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.

Key Developments in Global Atopic Dermatitis Drugs Market

  • In June 2022, the U.S. Food and Drug Administration (FDA) approved the first biologic Dupixent (dupilumab) for treatment of children aged six months to five years with moderate to severe dermatitis, when the disease is not adequately controlled with topical therapies
  • In January 2022, Pfizer announced that the U.S. FDA had approved its CIBINQO (abrocitinib) for treating adults with moderate to severe atopic dermatitis. CIBINQO (abrocitinib) is an oral drug that contains Janus kinase 1 (JAK1) inhibitors.

Each of these players has been profiled in the atopic dermatitis drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Atopic Dermatitis Drugs Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 6.0 Bn

Market Forecast Value in 2031

More than US$ 29.4 Bn

Growth Rate (CAGR) for 2022-2031

14.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Type
    • Corticosteroids
    • PDE4 Inhibitors
    • Biologics
    • Skin Barrier Emollients
    • CNI Immunosuppressants
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Mylan N.V.
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi
  • Novartis AG
  • Bausch Health
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global atopic dermatitis drugs market in 2021?

The global atopic dermatitis drugs market was valued at US$ 6.0 Bn in 2021

How big will be the global atopic dermatitis drugs market in 2031?

The global atopic dermatitis drugs market is projected to reach more than US$ 29.4 Bn by 2031

What will be the CAGR of the global atopic dermatitis drugs market during the forecast period (2022–2031)?

The global atopic dermatitis drugs market is anticipated to grow at a CAGR of 14.7% from 2022 to 2031

What is the market share of the leading segment of the global atopic dermatitis drugs market?

The biologics segment held around 76% share of the global atopic dermatitis drugs market in 2021

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global atopic dermatitis drugs market during the forecast period.

Who are the prominent players in the global atopic dermatitis drugs market?

Prominent players in the global atopic dermatitis drugs market are Mylan N.V., Pfizer, Inc., LEO Pharma A/S, Sanofi, Novartis AG, Bausch Health, and Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Atopic Dermatitis Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug Type Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Disease Epidemiology

        5.2. Pipeline Analysis

        5.3. Key Industry Events

        5.4. COVID-19 Impact Analysis

    6. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Drug Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug Type, 2017–2031

            6.3.1. Corticosteroids

            6.3.2. PDE4 Inhibitors

            6.3.3. Biologics

            6.3.4. Skin Barrier Emollients

            6.3.5. CNI Immunosuppressants

            6.3.6. Others

        6.4. Market Attractiveness Analysis, by Drug Type

    7. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Distribution Channel, 2017–2031

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Market Attractiveness Analysis, by Distribution Channel

    8. Global Atopic Dermatitis Drugs Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Atopic Dermatitis Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Drug Type, 2017–2031

            9.2.1. Corticosteroids

            9.2.2. PDE4 Inhibitors

            9.2.3. Biologics

            9.2.4. Skin Barrier Emollients

            9.2.5. CNI Immunosuppressants

            9.2.6. Others

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Drug Type

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Type, 2017–2031

            10.2.1. Corticosteroids

            10.2.2. PDE4 Inhibitors

            10.2.3. Biologics

            10.2.4. Skin Barrier Emollients

            10.2.5. CNI Immunosuppressants

            10.2.6. Others

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Drug Type

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Type, 2017–2031

            11.2.1. Corticosteroids

            11.2.2. PDE4 Inhibitors

            11.2.3. Biologics

            11.2.4. Skin Barrier Emollients

            11.2.5. CNI Immunosuppressants

            11.2.6. Others

        11.3. Market Value Forecast, by Distribution Channel, 2017–2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Drug Type

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Type, 2017–2031

            12.2.1. Corticosteroids

            12.2.2. PDE4 Inhibitors

            12.2.3. Biologics

            12.2.4. Skin Barrier Emollients

            12.2.5. CNI Immunosuppressants

            12.2.6. Others

        12.3. Market Value Forecast, by Distribution Channel, 2017–2031

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Drug Type

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Type, 2017–2031

            13.2.1. Corticosteroids

            13.2.2. PDE4 Inhibitors

            13.2.3. Biologics

            13.2.4. Skin Barrier Emollients

            13.2.5. CNI Immunosuppressants

            13.2.6. Others

        13.3. Market Value Forecast, by Distribution Channel, 2017–2031

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Drug Type

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company, 2021

        14.3. Company Profiles

            14.3.1. Mylan N.V.

                14.3.1.1. Company Description

                14.3.1.2. Business Overview

                14.3.1.3. Financial Overview

                14.3.1.4. Strategic Overview

                14.3.1.5. SWOT Analysis

            14.3.2. Pfizer, Inc.

                14.3.2.1. Company Description

                14.3.2.2. Business Overview

                14.3.2.3. Financial Overview

                14.3.2.4. Strategic Overview

                14.3.2.5. SWOT Analysis

            14.3.3. LEO Pharma A/S

                14.3.3.1. Company Description

                14.3.3.2. Business Overview

                14.3.3.3. Financial Overview

                14.3.3.4. Strategic Overview

                14.3.3.5. SWOT Analysis

            14.3.4. Sanofi

                14.3.4.1. Company Description

                14.3.4.2. Business Overview

                14.3.4.3. Financial Overview

                14.3.4.4. Strategic Overview

                14.3.4.5. SWOT Analysis

            14.3.5. Novartis AG

                14.3.5.1. Company Description

                14.3.5.2. Business Overview

                14.3.5.3. Financial Overview

                14.3.5.4. Strategic Overview

                14.3.5.5. SWOT Analysis

            14.3.6. Bausch Health

                14.3.6.1. Company Description

                14.3.6.2. Business Overview

                14.3.6.3. Financial Overview

                14.3.6.4. Strategic Overview

                14.3.6.5. SWOT Analysis

            14.3.7. Teva Pharmaceutical Industries Ltd.

                14.3.7.1. Company Description

                14.3.7.2. Business Overview

                14.3.7.3. Financial Overview

                14.3.7.4. Strategic Overview

                14.3.7.5. SWOT Analysis

    List of Tables

    Table 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 02: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031

    Table 03: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 05: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 06: North America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 07: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 08: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 09: Europe Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 10: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 12: Asia Pacific Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 15: Latin America Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 18: Middle East and Africa Atopic Dermatitis Drugs Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 03: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 04: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2031

    Figure 05: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by PDE4 Inhibitors, 2017–2031

    Figure 06: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Biologics, 2017–2031

    Figure 07: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Skin Barrier Emollients, 2017–2031

    Figure 08: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, CNI Immunosuppressants, 2017–2031

    Figure 09: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Others, 2017–2031

    Figure 10: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 11: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 12: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2017–2031

    Figure 13: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2017–2031

    Figure 14: Global Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, by Online Pharmacies, 2017–2031

    Figure 15: Global Atopic Dermatitis Drugs Market Value Share Analysis, by Region, 2021 and 2031

    Figure 16: Global Atopic Dermatitis Drugs Market Attractiveness Analysis, by Region, 2022–2031

    Figure 17: North America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 18: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Country, 2021 and 2031

    Figure 19: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country, 2022–2031

    Figure 20: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 21: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 22: North America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 23: North America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 24: Europe Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 25: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 26: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 27: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 28: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 29: Europe Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 30: Europe Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 31: Asia Pacific Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 32: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 33: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 34: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 35: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 36: Asia Pacific Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 37: Asia Pacific Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 38: Latin America Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 39: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 40: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 41: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 42: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 43: Latin America Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 44: Latin America Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 45: Middle East and Africa Atopic Dermatitis Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 46: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 47: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 48: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Drug Type, 2021 and 2031

    Figure 49: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 50: Middle East and Africa Atopic Dermatitis Drugs Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 51: Middle East and Africa Atopic Dermatitis Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy